The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment

Similar Items

• Dalbavancin dosage adjustments not required for patients with mild to moderate renal impairment
  od: Dowell, J, i dr.
  Izdano: (2008)
• Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
  od: Schnell, David, i dr.
  Izdano: (2014)
• Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment
  od: Desai, Amit, i dr.
  Izdano: (2016)
• Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
  od: Tortorici, Michael A., i dr.
  Izdano: (2010)
• Dalbavancin safety in the phase 2/3 clinical development program
  od: Seltzer, E, i dr.
  Izdano: (2008)